A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2022-10-18
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-09-13 (study day 313); relationship: N
mild
assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-09-16 (study day 316); relationship: not assessed
moderate
assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-18 (study day 440); relationship: not assessed
severe
assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-04 (study day 457); relationship: not assessed
Data queries
No data queries.